

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:)	Group Art Unit: To be
ANDREW C. HIATT and FLOYD ROSE)	Assigned
Serial No. 08/300,484)	Examiner: To be Assigned
Filed: September 1, 1994)	
For: ENZYME CATALYZED TEMPLATE- INDEPENDENT CREATION OF PHOSPHODIESTER BONDS USING PROTECTED NUCLEOTIDES)	

STATEMENT UNDER 37 C.F.R. § 1.821 (F)

Honorable Commissioner of
Patents and Trademarks
Washington, D.C. 20231

Sir:

I hereby state that the content of the paper and computer readable copies of the Sequence Listing, submitted in accordance with 37 C.F.R. § 1.821 (e), (f) and (g), or § 1.825 (d) and (b) respectively, are the same.

Respectfully submitted,

LYON & LYON

By: Jeffrey W. Guise
Jeffrey W. Guise
Registration No. 34,613

First Interstate World Center
633 West Fifth Street
Suite 4700
Los Angeles, CA 90071
(213) 489-1600

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the Commissioner of Patents and Trademarks, Washington, D.C. 20231

Feb. 6, 1995
Date of Deposit

Kim Arnold-Cabeller
Name of Person Mailing Paper
KACabeller
Signature of Person Mailing Paper

COPY

Best Available Copy

CRF Errors Corrected by the STIC Systems Branch

Serial Number: 081300, 454

CRF Processing Date: 3/30/95 #6

Edited by: AM

Verified by: STB (STIC staff)

1815
AU

4/14/95

ENTERED

- ☐ Changed a file from non-ASCII to ASCII
- ☐ Changed the margins in cases where the sequence text was "wrapped" down to the next line
- ☐ Edited a format error in the Current Application Data section, specifically: _____
- ☐ Edited the Current Application Data section with the actual current number. The number inputted by the applicant was ☐ the prior application data; or ☐ other _____
- ☐ Added the mandatory heading and subheadings for "Current Application Data".
- ☐ Edited the "Number of Sequences" field. The applicant spelled out a number instead of using an integer.
- ☐ Changed the spelling of a mandatory field (the headings or subheadings), specifically: _____
- ☒ Corrected the SEQ ID NO when obviously incorrect. The sequence numbers that were edited were:
Seq. 8 had a "10" in the SEQ ID NO. field
- ☐ Inserted or corrected a nucleic number at the end of a nucleic line. SEQ ID NO's edited: _____
- ☐ Corrected subheading placement. All responses must be on the same line as each subheading. If the applicant placed a response below the subheading, this was moved to its appropriate place.
- ☐ Inserted colons after headings/subheadings. Headings edited included: _____
- ☐ Deleted extra, invalid, headings used by an applicant, specifically: _____
- ☐ Deleted: ☐ non-ASCII "garbage" at the beginning/end of files; ☐ secretary initials/filename at end of file; ☐ page numbers throughout text; ☐ other invalid text, such as _____
- ☐ Inserted mandatory headings, specifically: _____
- ☐ Corrected an obvious error in the response, specifically: _____
- ☐ Edited identifiers where upper case is used but lower case is required, or vice versa.
- ☐ Corrected an error in the Number of Sequences field, specifically: _____
- ☒ A "Hard Page Break" code was inserted by the applicant. All occurrences had to be deleted.
- ☐ Deleted **ending** stop codon in amino acid sequences and adjusted the "(A)Length:" field accordingly (error due to a PatentIn bug). Sequences corrected: _____
- ☐ Other: _____

*Examiner: The above corrections must be communicated to the applicant in the first Office Action. DO NOT send a copy of this form.

3/1/95

RAW SEQUENCE LISTING
PATENT APPLICATION US/08/300,484DATE: 03/30/95
TIME: 21:01:20

INPUT SET: S3019.raw

This Raw Listing contains the General
Information Section and up to the first 5 pages.

ENTERED

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

SEQUENCE LISTING

(1) General Information:

(i) APPLICANT: Andrew C. Hiatt, Floyd Rose

(ii) TITLE OF INVENTION: ENZYME CATALYZED TEMPLATE-
INDEPENDENT CREATION OF
PHOSPHODIESTER BONDS USING
PROTECTED NUCLEOTIDES

(iii) NUMBER OF SEQUENCES: 8

(iv) CORRESPONDENCE ADDRESS:

(A) ADDRESSEE: Lyon & Lyon
(B) STREET: 633 West Fifth Street
Suite 4700
(C) CITY: Los Angeles
(D) STATE: California
(E) COUNTRY: U.S.A.
(F) ZIP: 90071

(v) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
storage
(B) COMPUTER: IBM Compatible
(C) OPERATING SYSTEM: IBM P.C. DOS 5.0
(D) SOFTWARE: Word Perfect 5.1

(vi) CURRENT APPLICATION DATA:

(A) APPLICATION NUMBER: 08/300,484
(B) FILING DATE: September 1, 1994
(C) CLASSIFICATION:

(vii) PRIOR APPLICATION DATA:

Prior applications total,
including application
described below: none

(viii) ATTORNEY/AGENT INFORMATION:

(A) NAME: Guise, Jeffrey W.

RAW SEQUENCE LISTING
PATENT APPLICATION US/08/300,484DATE: 03/30/95
TIME: 21:01:23

INPUT SET: S3019.raw

47 (B) REGISTRATION NUMBER: 34,613
48 (C) REFERENCE/DOCKET NUMBER: 207/145
49
50 (ix) TELECOMMUNICATION INFORMATION:
51
52 (A) TELEPHONE: (619) 552-8400
53 (B) TELEFAX: (619) 552-0159
54 (C) TELEX: 67-3510
55
56 (2) INFORMATION FOR SEQ ID NO: 1:
57
58 (i) SEQUENCE CHARACTERISTICS:
59
60 (A) LENGTH: 12
61 (B) TYPE: nucleic acid
62 (C) STRANDEDNESS: single
63 (D) TOPOLOGY: linear
64
65 (ix) FEATURE:
66
67 (D) OTHER INFORMATION: base number 12 is m7g
68
69
70 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:
71
72 CCCCCCCCC CG 12
73
74
75
76 (2) INFORMATION FOR SEQ ID NO: 2:
77
78 (i) SEQUENCE CHARACTERISTICS:
79
80 (A) LENGTH: 19
81 (B) TYPE: nucleic acid
82 (C) STRANDEDNESS: single
83 (D) TOPOLOGY: linear
84
85 (ii) SEQUENCE DESCRIPTION: SEQ ID NO: 2:
86
87 CCCCCCCCC CCCCCTGCA 19
88
89
90
91 (2) INFORMATION FOR SEQ ID NO: 3:
92
93 (i) SEQUENCE CHARACTERISTICS:
94
95 (A) LENGTH: 20
96 (B) TYPE: nucleic acid
97 (C) STRANDEDNESS: single
98 (D) TOPOLOGY: linear
99

RAW SEQUENCE LISTING
PATENT APPLICATION US/08/300,484DATE: 03/30/95
TIME: 21:01:26

INPUT SET: S3019.raw

```
100          (ii) SEQUENCE DESCRIPTION: SEQ ID NO: 3:
101
102 CTGCAGGGGG GGGGGGGGGG                20
103
104
105
106
107
108
109
110
111 (2) INFORMATION FOR SEQ ID NO: 4:
112
113          (i) SEQUENCE CHARACTERISTICS:
114
115              (A) LENGTH:          9
116              (B) TYPE:            nucleic acid
117              (C) STRANDEDNESS:    single
118              (D) TOPOLOGY:       linear
119
120          (ii) SEQUENCE DESCRIPTION: SEQ ID NO: 4:
121
122 CCCCCCCCC                9
123
124
125 (2) INFORMATION FOR SEQ ID NO: 5:
126
127          (i) SEQUENCE CHARACTERISTICS:
128
129              (A) LENGTH:          9
130              (B) TYPE:            nucleic acid
131              (C) STRANDEDNESS:    single
132              (D) TOPOLOGY:       linear
133
134          (ii) SEQUENCE DESCRIPTION: SEQ ID NO: 5:
135
136 GGGGGGGGG                9
137
138
139 (2) INFORMATION FOR SEQ ID NO: 6:
140
141          (i) SEQUENCE CHARACTERISTICS:
142
143              (A) LENGTH:          5
144              (B) TYPE:            nucleic acid
145              (C) STRANDEDNESS:    single
146              (D) TOPOLOGY:       linear
147
148          (ii) SEQUENCE DESCRIPTION: SEQ ID NO: 6:
149
150 CTGCA                5
151
152 (2) INFORMATION FOR SEQ ID NO: 7:
```

RAW SEQUENCE LISTING
PATENT APPLICATION US/08/300,484DATE: 03/30/95
TIME: 21:01:28

INPUT SET: S3019.raw

153

154

(i) SEQUENCE CHARACTERISTICS:

155

156

(A) LENGTH: 9

157

(B) TYPE: nucleic acid

158

(C) STRANDEDNESS: single

159

(D) TOPOLOGY: linear

160

161

(ii) SEQUENCE DESCRIPTION: SEQ ID NO: 7:

162

163 CTGCATGCA

9

164

165

166

(2) INFORMATION FOR SEQ ID NO: 8:

167

168

(i) SEQUENCE CHARACTERISTICS:

169

170

(A) LENGTH: 10

171

(B) TYPE: nucleic acid

172

(C) STRANDEDNESS: single

173

(D) TOPOLOGY: linear

174

175

(ii) SEQUENCE DESCRIPTION: SEQ ID NO: 8:

176

177 CTGCATGCAG

10

178

179

180

181

182

RAW SEQUENCE LISTING
PATENT APPLICATION US/08/300,484DATE: 03/30/95
TIME: 21:01:30

INPUT SET: S3019.raw

***** PREVIOUSLY ERRORED SEQUENCES - EDITED *****

166 (2) INFORMATION FOR SEQ ID NO: 8:
167
168 (i) SEQUENCE CHARACTERISTICS:
169
170 (A) LENGTH: 10
171 (B) TYPE: nucleic acid
172 (C) STRANDEDNESS: single
173 (D) TOPOLOGY: linear
174
175 (ii) SEQUENCE DESCRIPTION: SEQ ID NO: 8:
176
177 CTGCATGCAG 10
178
179
180
181
182

PAGE: 1

SEQUENCE VERIFICATION REPORT
PATENT APPLICATION US/08/300,484

DATE: 03/30/95
TIME: 21:01:31

INPUT SET: S3019.raw

Line

Error

Original Text

RAW SEQUENCE LISTING
PATENT APPLICATION US/08/300,484DATE: 03/30/95
TIME: 15:57:21

INPUT SET: S3019.raw


This Raw Listing contains the General
Information Section and those Sequences
containing ERRORS.

SEQUENCE LISTING

1
2
3 (1) General Information:
4
5 (i) APPLICANT: Andrew C. Hiatt, Floyd Rose
6
7 (ii) TITLE OF INVENTION: ENZYME CATALYZED TEMPLATE-
8 INDEPENDENT CREATION OF
9 PHOSPHODIESTER BONDS USING
10 PROTECTED NUCLEOTIDES
11
12 (iii) NUMBER OF SEQUENCES: 8
13
14 (iv) CORRESPONDENCE ADDRESS:
15
16 (A) ADDRESSEE: Lyon & Lyon
17 (B) STREET: 633 West Fifth Street
18 Suite 4700
19 (C) CITY: Los Angeles
20 (D) STATE: California
21 (E) COUNTRY: U.S.A.
22 (F) ZIP: 90071
23
24 (v) COMPUTER READABLE FORM:
25
26 (A) MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
27 storage
28 (B) COMPUTER: IBM Compatible
29 (C) OPERATING SYSTEM: IBM P.C. DOS 5.0
30 (D) SOFTWARE: Word Perfect 5.1
31
32 (vi) CURRENT APPLICATION DATA:
33
34 (A) APPLICATION NUMBER: 08/300,484
35 (B) FILING DATE: September 1, 1994
36 (C) CLASSIFICATION:
37
38 (vii) PRIOR APPLICATION DATA:
39
40 Prior applications total,
41 including application
42 described below: none
43
44 (viii) ATTORNEY/AGENT INFORMATION:
45


RAW SEQUENCE LISTING
PATENT APPLICATION US/08/300,484DATE: 03/30/95
TIME: 15:57:26

INPUT SET: S3019.raw

46 (A) NAME: Guise, Jeffrey W.
47 (B) REGISTRATION NUMBER: 34,613
48 (C) REFERENCE/DOCKET NUMBER: 207/145
49
50 (ix) TELECOMMUNICATION INFORMATION:
51
52 (A) TELEPHONE: (619) 552-8400
53 (B) TELEFAX: (619) 552-0159
54 (C) TELEX: 67-3510(2) INFORMATION FOR SEQ ID NO:
55
--> 56 (i) SEQUENCE CHARACTERISTICS:  *remove hard page break code*
57
--> 58 (A) LENGTH: 12
--> 59 (B) TYPE: nucleic acid
--> 60 (C) STRANDEDNESS: single
--> 61 (D) TOPOLOGY: linear
62
--> 63 (ix) Features:
64
--> 65 (D) Other Information: base number 12 is m7g
66
67
--> 68 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:
69
70 CCCCCCCCCC CG 12
71
72
73

ERRORED SEQUENCES FOLLOW:

164 (2) INFORMATION FOR SEQ ID NO: 8:
165
166 (i) SEQUENCE CHARACTERISTICS:
167
168 (A) LENGTH: 10
169 (B) TYPE: nucleic acid
170 (C) STRANDEDNESS: single
171 (D) TOPOLOGY: linear
172
--> 173 (ii) SEQUENCE DESCRIPTION: SEQ ID NO: 10
174
175 CTGCATGCAG 10
176
177
178
179



SEQUENCE VERIFICATION REPORT
PATENT APPLICATION US/08/300,484DATE: 03/30/95
TIME: 15:57:29**INPUT SET: S3019.raw**

Line	Error	Original Text
12	Number of Sequences (8) Doesn't Equal Actual Count (7)	(iii) NUMBER OF SEQUENCES: 8
56	Unknown or Misplaced Identifier	(i) SEQUENCE CHARACTERISTICS:
58	Unknown or Misplaced Identifier	(A) LENGTH: 12
59	Unknown or Misplaced Identifier	(B) TYPE: nucleic acid
60	Unknown or Misplaced Identifier	(C) STRANDEDNESS: single
61	Unknown or Misplaced Identifier	(D) TOPOLOGY: linear
63	Unknown or Misplaced Identifier	(ix) Features:
65	Unknown or Misplaced Identifier	(D) Other Information: base number 12 is m7g
68	Unknown or Misplaced Identifier	(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:
173	Wrong Sequence Number	(ii) SEQUENCE DESCRIPTION: SEQ ID NO: 10: